MAPT and Alzheimer disease: Although promising results on plasma biomarkers, e.g., Aβ(1–42) (Aβ42) reductions [11–13] or increases in phosphorylated tau [14] have recently been reported, the accuracy of the combination of plasma biomarkers in predicting amyloid status in individuals at the preclinical or prodromal stages of AD has not been fully investigated.